361 Capital’s Kyntra Bio KYNB Stock Holding History

361 Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,217	Closed	-$2.05M	–	343
2019 Q3	$2.05M	Buy	+2,217	New	+$2.43M	0.38%	147

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

361 Capital's KYNB Position: Q4 2019 in Review

361 Capital sold out of Kyntra Bio (KYNB) in Q4 2019, closing a stake of 2,217 shares — an estimated $2.05M sold.

361 Capital first reported a position in KYNB in Q3 2019 and held it in 1 quarter. The position peaked at $2.05M in Q3 2019. 213 funds tracked by Wall St. Rank hold KYNB as of Q4 2019.

361 Capital reported no remaining Kyntra Bio position as of Q4 2019 after selling out during the quarter.
361 Capital sold 2,217 Kyntra Bio shares in Q4 2019, an estimated $2.05M.
361 Capital first reported a position in Kyntra Bio in Q3 2019 and held it in 1 quarter.
361 Capital's Kyntra Bio position peaked at $2.05M in Q3 2019.
213 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2019.

Based on 361 Capital's 13F filing for Q4 2019, filed 13 Feb 2020.